Alkermes plc. Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31)
Alkermes plc. (ALKS) had Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) of $5.88 as of 2014-03-31, per its 10-Q filed 2014-04-30.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExercisePrice · last filed 2014-04-30
- 2014-03-31: Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) $5.88.
- 2013-12-31: Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) $5.88.
| Period end | Fair Value Assumptions, Exercise Price (Deprecated 2018-01-31) |
|---|---|
| 2014-03-31 | $5.88 10-Q · filed 2014-04-30 |
| 2013-12-31 | $5.88 10-KT · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |